<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="587755" id="root" date="1997-05-15" xml:lang="en">
<title>SWITZERLAND: Societe General neutral on Roche.</title>
<headline>Societe General neutral on Roche.</headline>
<dateline>ZURICH 1997-05-15</dateline>
<text>
<p>A Societe Generale share analyst maintained a neutral rating on Roche one day after a U.S. Food and Drug Administration panel unanimously recommended approval of Xenical, the Swiss pharma concern's weight-loss drug.</p>
<p>Equities analyst Arnaud Delepine said he was less optimistic than Roche in terms of expectations for sales of Xenical. Delepine said sales potential was more likely to be between 400 million and 500 million Swiss francs, compared with the 700 million Swiss francs he said Roche was expecting.</p>
<p>&quot;Although the treatment definitely produces significant results, they are not really exceptional,&quot; he said of Xenical.</p>
<p>Redux, a competitor product, was also launched in 1996 by American Home Products. There were also uncertainties about long-term effects of treatment with Xenical, he said.</p>
<p>In addition, Delephine noted there were gastrointestinal reactions in some patients to Xenical.</p>
<p>But he said the product would be important for Roche nonetheless, adding the neutral rating would be maintained based on expectations of increased marketing costs for various products, and on the fact that Roche's financing account made a large contribution to earnings.</p>
<p>-- Zurich Editorial, +41 1 631 7340 accounting for</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="SWITZ">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25000">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
  <code code="C152">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
  <code code="C22">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-15"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-05-15"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-05-15"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="ZURICH"/>
<dc element="dc.creator.location.country.name" value="SWITZERLAND"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
